Navigation Links
Jefferson researcher awarded Landenberger Foundation grant for ALS research

PHILADELPHIA Piera Pasinelli, Ph.D., co-director of the Frances and Joseph Weinberg Unit for ALS Research at the Farber Institute for Neurosciences at Thomas Jefferson University was recently awarded a Margaret Q. Landenberger Research Foundation grant to identify why drug therapies that showed promise in Amyotrophic Lateral Sclerosis (ALS) mouse models have proven unsuccessful in human clinical trials. Dr. Pasinelli and her research team will closely examine critical aspects of drug delivery in the central nervous system at the metabolic level with the hope of advancing drug development for ALS. The grant totals $300,000 and will be issued in $100,000 disbursements over three years.

"In spite of recent progress toward understanding the origination of ALS, finding an effective treatment has remained elusive. Our hypothesis is that one reason there is no viable drug therapy for ALS may be that in designing both mouse and human clinical trials, scientists have overlooked critical aspects of drug bioavailability and metabolism." said Dr. Pasinelli. "Proteins called multi-drug resistance transporters are increased during the disease, rendering pharmacological treatments for ALS mostly ineffective. This grant will support research towards finding ways to inactivate these transporter proteins to counteract their negative effect on ALS therapy. We are extremely grateful to the Margaret Q. Landenberger Research Foundation for seeing the potential our work has and awarding us this grant money."

The Margaret Q. Landenberger Research Foundation, which was formed in 1992, is based in Philadelphia, Pennsylvania. Brown Brothers Harriman Trust Company, N.A., serves as the foundation's corporate trustee.

"The Landenberger Foundation provides initial funding for novel medical research projects in the hope that this will help the scientists further expand their research through additional grants from other sources," said William R. Levy, Executive Vice President, who oversees the operations of the foundation for the Brown Brothers Harriman Trust Company. "Although it is a small foundation, it has an excellent scientific advisory board that helps direct the grant-making decisions. The Foundation's mission is to be at the cutting edge of medical research."

ALS, commonly known as Lou Gehrig's disease or motor neuron disease, is a progressive neurodegenerative disease that affects nerve cells in the brain and the spinal cord. Motor neurons reach from the brain to the spinal cord and from the spinal cord to the muscles throughout the body. The progressive degeneration of the motor neurons in ALS eventually leads to their death. When the motor neurons die, the ability of the brain to initiate and control muscle movement is lost. With voluntary muscle action progressively affected, patients in the later stages of the disease may become totally paralyzed. According to the ALS Association, every year about 5,600 people are diagnosed with the disease, which is currently untreatable.


Contact: Ed Federico
Thomas Jefferson University

Related biology news :

1. Jefferson scientists discover a key protein regulator of inflammation and cell death
2. Jefferson Department of Surgery announces new pancreas tumor registry
3. Jefferson scientists deliver toxic genes to effectively kill pancreatic cancer cells
4. Jefferson receives $11.6M NIH grant to study novel mechanisms of heart failure
5. Jefferson scientists studying the effects of high-dose vitamin C on non-Hodgkin lymphoma patients
6. Jefferson urologists studying regenerated neo-bladder to help spinal cord injury patients
7. CSHL researchers explain process by which cells hide potentially dangerous DNA segments
8. ISU researcher identifies protein that concentrates carbon dioxide in algae
9. Stem cell therapy makes cloudy corneas clear, according to Pitt researchers
10. Biomedical researchers invited to design experiments for the International Space Station
11. Caltech researchers train computers to analyze fruit-fly behavior
Post Your Comments:
(Date:10/5/2015)... ) releases ... (NASDAQ: NXTD ), a biometric authentication company focused ... ) releases the following market and ... a biometric authentication company focused on the growing mobile ... ) releases the following market and ...
(Date:10/1/2015)... Oct. 1, 2015  Biometrics includes diverse set ... body characteristics, such as fingerprints, eye retinas, facial ... of biometrics technology has been constantly increasing in ... five years. In addition to the most prominent ... recognition, other means of biometric authentication are rapidly ...
(Date:9/30/2015)... , Sept. 30, 2015  The U.S. Court of ... another key ruling in favor of Crossmatch ™, ... fingerprint scanner company Suprema and its U.S. partner Mentalix ... a trade provision that declares it unlawful to engage ... infringing two of Crossmatch,s patents, the 5,900,993 patent and ...
Breaking Biology News(10 mins):
(Date:10/12/2015)... , Oct. 12, 2015 VolitionRx Limited ... a completed clinical study of its NuQ ® blood-based ... the online issue of Clinical Epigenetics , the official ... conducted in collaboration with Lund University, ... Andersson , MD, PhD, Professor of Surgery and Vice-Dean, Faculty ...
(Date:10/11/2015)... ... October 11, 2015 , ... ... has been officially launched and multiple surgeries have been completed with this new ... of the Neuroscience & Spine Center of the Carolinas. The Revolution™ Spinal ...
(Date:10/9/2015)... -- Governor Tom Wolf announced today that ... developing T-cell receptor cancer immunotherapy treatments, will create at ... project. Pennsylvania , and today,s ... new, high-paying jobs will be created with this project," ... includes sustained funding for the life science sector and ...
(Date:10/9/2015)... ... October 09, 2015 , ... From blood to food ... those cells from their surroundings for research, diagnostics, and cell therapy—also known as ... this, Ann Arbor-based startup Akadeum Life Sciences is developing a radically ...
Breaking Biology Technology: